Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02095730
Other study ID # CXL-CHR 1
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received March 20, 2014
Last updated March 21, 2014
Start date May 2014

Study information

Verified date March 2014
Source Crowd Health Research, LTD
Contact Travis A Johnson, Bachelor's
Phone 571-234-5678
Email tjohnson@libertylasereye.com
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the Safety and Efficacy of Corneal Cross Linking in a Continuous Beam versus Pulsed Treatments across epithelium on and epithelium off surfaces.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 500
Est. completion date
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender Both
Age group 12 Years and older
Eligibility Inclusion Criteria Keratoconus:

- 12 years of age or older

- Having a clinical diagnosis of progressive keratoconus consistent with:

1. An increase of = 1.00 D in the steepest keratometry value

2. An increase of = 1.00 D in astigmatism manifest refraction

3. A myopic shift (decrease in the spherical equivalent) of = 0.50 D on subjective manifest refraction

- Presence of central or inferior steepening on the topography map.

- Axial topography consistent with keratoconus

- Steepest keratometry (Kmax) value = 47.00 D

- Signed written informed consent

- Willingness and ability to comply with schedule for follow-up visits

- Contact lens removal prior to evaluation and treatment

Inclusion Criteria Post-Surgical Ectasia:

- History of having undergone a keratorefractive procedure and:

1. Steepening by topography

2. Thinning of cornea

3. Shift in the position of thinnest portion of cornea

4. Change in refraction with increasing myopia

5. Development of myopic astigmatism

6. Development of irregular astigmatism

7. Loss of Best Spectacle Corrected Visual Acuity

- At least two of the above criteria must be present.

Inclusion Criteria Intacts:

- Should the patient have undergone prior Intacs or other intra-corneal ring segment surgery for keratoconus or post-surgical ectasia at least 6 months prior, and is also experiencing at least two of the above ectasia symptoms, they can be included in the study.

1. These patients would have the choice of ring explant before Cross-Linking.

2. Cross-Linking may still be performed if the patient wishes to retain the rings.

- Should a patient's situation due to factors such as significantly high myopia or astigmatism should warrant simultaneous placement of Intacs and cross-linking in the investigators opinion, then this option can be offered to the patient. Such interventions would be tracked as a different arm of the study.

Inclusion Criteria RK/AK Fluctuation:

- History of having undergone radial keratotomy (RK) and or astigmatic keratotomy (AK) surgery.

- Expressing complaints about difficulties due to vision changing during the same day.

- A difference in their Manifest Refraction (MRx) of greater than 0.75 D measured on the same day, at least 6 hours apart.

- Intacs surgery will not be considered in patients with RK/AK.

Exclusion Criteria:

- Eyes classified as either normal, atypical normal,

- Corneal pachymetry = 350 microns at the thinnest point measured by Orbscan, Pentacam, or ultrasound in the eye to be treated

- A history of chemical injury or delayed epithelial healing in the eye to be treated.

- A known sensitivity to study medications

- Patients with significant nystagmus or any other condition that would prevent a steady gaze during the treatment

- Inability to cooperate with diagnostic tests.

- Patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing.

- Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking treatment.

- Patients who are unable to remain comfortable and stable, and tolerate a lid speculum for the appointed period of time for the procedure.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Epithelium-On Riboflavin
Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
Epithelium-Off Riboflavin
Riboflavin 0.1% Phosphate Sodium solution
Device:
UV Light - Continuous Beam
5 minutes of constant UV exposure to saturated cornea
UV Pulsed Beam
5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes

Locations

Country Name City State
United States Eye Consultants of Atlanta Atlanta Georgia
United States Icon Lasik Denver Colorado
United States Midwest Center for Sight Des Plaines Illinois
United States James Lewis MD PC Elkins Park Pennsylvania
United States Loden Vision Centers Goodlettsville Tennessee
United States Memorial Eye Institute Harrisburg Pennsylvania
United States Southern Eye Center Hattiesburg Mississippi
United States Gulani Vision Institute Jacksonville Florida
United States LASIK of Nevada Las Vegas Nevada
United States Discover Vision Center Leawood Kansas
United States Carolina Eye Care Mt. Pleasant South Carolina
United States Bond Eye Associates Pekin Illinois
United States Parkhurst NuVision San Antonio Texas
United States LaserVue Eye Santa Rosa California
United States Mercy Clinic Eye Specialists Springfield Missouri
United States Liberty Laser Eye Center Vienna Virginia

Sponsors (1)

Lead Sponsor Collaborator
Crowd Health Research, LTD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Acuity Uncorrected visual acuity 2 years Yes